Title: Impact of Steatotic Liver Disease Subtypes, Sarcopenia, and Fibrosis on All-cause and
Cause-specific Mortality: A 15.7-year Cohort Study
Version: 0 Date: 12 Dec 2024
Reviewer's report:
The paper from Liang et al evaluated the association between SLD and sarcopenia with mortality
in the NHANES data set.  There were some limitations as US and BIA were not available in the
same NHANES data sets.  This led to the utilization of a model to estimate the prevalence of
steatosis (FLI).  I would consider addressing the following issues
1.  I would remove data regarding "MAFLD/NAFLD".  It is confusing and does not align with
updated definitions.
2. The FLI mostly would account for what would be considered as MASLD given its reliance
on factors- TG, BMI, GGT and WC.  This is a limitation as much of SLD (alcohol and other)
may be missed by utilizing this model. This should be acknowledged as a limitation
3. why did the authors choose  that model for defining sarcopenia when others have been already
used for the US population in NHANES (Euro J gastro and hep 2019;31:1121-1128)
4. I believe it stated so in the methods, but could the authors clarify that appropriate sampling
waiting was done per NHANES guidelines?
Title: Impact of Steatotic Liver Disease Subtypes, Sarcopenia, and Fibrosis on All-cause and
Cause-specific Mortality: A 15.7-year Cohort Study
Version: 0 Date: 12 Dec 2024
Reviewer's report:
The paper from Liang et al evaluated the association between SLD and sarcopenia with mortality
in the NHANES data set.  There were some limitations as US and BIA were not available in the
same NHANES data sets.  This led to the utilization of a model to estimate the prevalence of
steatosis (FLI).  I would consider addressing the following issues
1.  I would remove data regarding "MAFLD/NAFLD".  It is confusing and does not align with
updated definitions.
2. The FLI mostly would account for what would be considered as MASLD given its reliance
on factors- TG, BMI, GGT and WC.  This is a limitation as much of SLD (alcohol and other)
may be missed by utilizing this model. This should be acknowledged as a limitation
3. why did the authors choose  that model for defining sarcopenia when others have been already
used for the US population in NHANES (Euro J gastro and hep 2019;31:1121-1128)
4. I believe it stated so in the methods, but could the authors clarify that appropriate sampling
waiting was done per NHANES guidelines?
Please review this paper.
user
Title: Impact of Steatotic Liver Disease Subtypes, Sarcopenia, and Fibrosis on All-cause and
Cause-specific Mortality: A 15.7-year Cohort Study
Version: 0 Date: 12 Dec 2024
Reviewer's report:
The paper from Liang et al evaluated the association between SLD and sarcopenia with mortality
in the NHANES data set.  There were some limitations as US and BIA were not available in the
same NHANES data sets.  This led to the utilization of a model to estimate the prevalence of
steatosis (FLI).  I would consider addressing the following issues
1.  I would remove data regarding "MAFLD/NAFLD".  It is confusing and does not align with
updated definitions.
2. The FLI mostly would account for what would be considered as MASLD given its reliance
on factors- TG, BMI, GGT and WC.  This is a limitation as much of SLD (alcohol and other)
may be missed by utilizing this model. This should be acknowledged as a limitation
3. why did the authors choose  that model for defining sarcopenia when others have been already
used for the US population in NHANES (Euro J gastro and hep 2019;31:1121-1128)
4. I believe it stated so in the methods, but could the authors clarify that appropriate sampling
waiting was done per NHANES guidelines?
assistant